Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117689 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
A Phase 2 study of Liver Dysfunction and Transplantation, Liver, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 16
- Study locations
NCT00117689: Completed Phase 2 study of Liver Dysfunction and Transplantation, Liver, sponsored by Genzyme, a Sanofi Company.
NCT00117689 is a Phase 2 study of Liver Dysfunction and Transplantation, Liver that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 75 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00117689, a Phase 2 study of Liver Dysfunction and Transplantation, Liver, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and prevent kidney transplant rejection. This study will evaluate the effect of Thymoglobulin induction therapy and reduced doses of calcineurin inhibitors on the incidence of liver rejection and will provide a basis for future evaluations of Thymoglobulin as an immunosuppressive agent to help decrease the incidence of liver transplant rejection. Subjects meeting all inclusion and exclusion criteria are eligible to participate in this study. Approximately 75 study subjects from up to 18 transplant centers in the United States and Canada will be enrolled in this 12-month study.
Conditions Studied
Interventions
- DRUG Corticosteroid
- DRUG Mycophenolate Mofetil
- DRUG Tacrolimus
- BIOLOGICAL Thymoglobulin
Study Locations (16)
California
- USC University Hospital - Los Angeles
- University of California, San Fransisco Hospital - San Francisco
Florida
- Mayo Clinic Jacksonville - Jacksonville
- University of Miami - Miami
Texas
- Baylor University Medical Center - Dallas
- University of Texas Health Science Center at San Antonio, University Hospital - San Antonio
Alabama
- University of Alabama, Birmingham - Birmingham
Colorado
- University of Colorado Hospital and Health Sciences Center - Denver
Minnesota
- Fairview University Medical Center - Minneapolis
Missouri
- Washington University Medical Center - St Louis
Nebraska
- University of Nebraska - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
What the finished NCT00117689 record still lists
NCT00117689 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (44% lower).
The record links to 3 conditions, with Liver Dysfunction appearing as the primary indexed condition, and to 4 interventions - of which Corticosteroid is the first listed.
NCT00117689 lists 16 locations in 13 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT00117689 about?
NCT00117689 is a clinical study titled "Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection". This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and prevent kidney transplant rejection. This study will evaluate the effect of Thymoglobulin induction therapy and reduced doses of calcineurin inhibit...
What is the current status of trial NCT00117689?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2005-04. Estimated completion is 2007-12.
What conditions does trial NCT00117689 study?
This clinical trial studies the following conditions: Liver Dysfunction, Transplantation, Liver, Rejection, Transplant.
What interventions are being tested in trial NCT00117689?
The interventions under investigation include: Corticosteroid (DRUG), Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Thymoglobulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00117689?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00117689 being conducted?
This trial has 16 study locations across Alabama, California, Colorado, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00117689's enrollment target sits among peer trials
75 900th of 2000 higher than 1,081 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia